Simvastatin treatment reduces the cholesterol content of membrane/lipid rafts, implicating the N -methyl-D-aspartate receptor in anxiety: a literature review

AUTOR(ES)

Cruz, Júlia Niehues da, Magro, Débora Delwing Dal, Lima, Daniela Delwing de, Cruz, José Geraldo Pereira da

FONTE

Braz. J. Pharm. Sci.

DATA DE PUBLICAÇÃO

20/04/2017

RESUMO

ABSTRACT Membrane/lipid rafts (MLRs) are plasmalemmal microdomains that are essential for neuronal signaling and synaptic development/stabilization. Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase (statins) can disable the N-methyl-D-aspartate (NMDA) receptor through disruption of MLRs and, in turn, decrease NMDA-mediated anxiety. This hypothesis will contribute to understanding the critical roles of simvastatin in treating anxiety via the NMDA receptor.

Documentos Relacionados

• Cholesterol, lipid rafts, and disease
• N-methyl-D-aspartate receptor plasticity in kindling: quantitative and qualitative alterations in the N-methyl-D-aspartate receptor-channel complex.
• Interventions for music performance anxiety: results from a systematic literature review
• The fyn art of N-methyl-d-aspartate receptor phosphorylation
• Protein kinase C potentiation of N-methyl-d-aspartate receptor activity is not mediated by phosphorylation of N-methyl-d-aspartate receptor subunits